Advanced search
Publication Cover
International Journal of Radiation Biology Volume 77, 2001 - Issue 2
Submit an article Journal homepage
38
Views
59
CrossRef citations to date
0
Altmetric
Research Article

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues

R. Murata, J. Overgaard, M. R. Horsman Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, Building 5, DK-8000 Aarhus C, Denmark
Pages 195-204 | Published online: 03 Jul 2009

  • BOEHM, T., FOLKMAN, J., BRODER, T. and O'REILLY, M. S., 1997, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-407.
  • CHAPLIN, D. J. and DOUGHERTY, G. J., 1999, Tumour vasculature as a target for cancer therapy. British Journal of Cancer, 80 (Suppl. 1), 57-64.
  • CHAPLIN, D. J., PETTIT, G. R. and HILL, S. A., 1999, Antivascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Research, 19, 189-196.
  • CHAPLIN, D. J., PETTIT, G. R., PARKINS, C. S. and HILL, S. A., 1996, Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. British Journal of Cancer, 74 (Suppl. XXVII), S86-S88.
  • CHING, L.-M., JOSEPH, W. R., CROSIER, K. E. and BAGULEY, B. C., 1994, Induction of tumor necrosis factor-a messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Research, 54, 870-872.
  • CLIFFE, S., TAYLOR, M. L., RUTLAND, M., BAGULEY, B. C., HILL, R. P. and WILSON, W. R., 1994, Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. International Journal of Radiation Oncology, Biology, Physics, 29, 373-377.
  • DARK, G. G., HILL, S. A., PRISE, V. E., TOZER, G. M., PETTIT, G. R. and CHAPLIN, D. J., 1997, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Research, 57, 1829-1834.
  • DENEKAMP, J. and HILL, S. A., 1991, Angiogenic attack as a therapeutic strategy for cancer. Radiotherapy and Oncology, 20, 103-112.
  • DENEKAMP, J., HILL, S. A. and HOBSON, B., 1983, Vascular occlusion and tumour cell death. European Journal of Cancer, 19, 271-275.
  • FOLKMAN, J., 1997, Antiangiogenic Therapy. In: Cancer: Principles & Practice of Oncology, edited by V. T. Jr Devita, S. Hellman and S. A. Rosenberg (Philadelphia, PA: Lippincott-Raven Publishers), pp. 3075-3085.
  • GROSIOS, K., HOLWELL, S. E., McGOWN, A. T., PETTIT, G. R. and BlBBY, M. C., 1999, In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. British Journal of Cancer, 81, 1318-1327.
  • HORSMAN, M. R., CHRISTENSEN, K. L. and OVERGAARD, J., 1989, Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vino. International Journal of Hyperthermia, 5, 123-136.
  • HORSMAN, M. R., EHRNROOTH, E., LADEKARL, M. and OVERGAARD, J., 1998, The efiect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. International Journal of Radiation Oncology, Biology, Physics, 42, 895-898.
  • HORSMAN, M. R., MURATA, R., BREIDAHL, T., NIELSEN, F. U., MAXWELL, R. J., STØDKILDE-JØRGENSEN, H. and OVERGAARD, J., 2000, Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. In: Angiogmesis: From Molecular to Integrative Pharmacology, edited by M. E. Maragoudakis (New York: Kluwer Academic/ Plenum Publishers), pp. 311-323.
  • HORSMAN, M. R., SAMPSON, L. E., CHAPLIN, D. J. and OVERGAARD, J., 1996, The in vivo interaction between flavone acetic acid and hyperthermia. International Journal of Hyperthermia, 12, 779-789.
  • IYER, S., CHAPLIN, D. J., ROSENTHAL, D. S., BOULARES, A. H., Ll, L.-Y. and SMULSON, M. E., 1998, Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Research, 58, 4510-4514.
  • JOSEPH, W. R., CAO, Z., MOUNTJOY, K. G., MARSHALL, E. S., BAGULEY, B. C. and CHING, L.-M., 1999, Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Research, 59, 633-638.
  • LASH, C. J., LI, A. E., RUTLAND, M., BAGULEY, B. C., ZWI, L. J. and WILSON, W. R., 1998, Enhancement of the antitumour effects of the antivascular agent 5,6-dimethylxan-thenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. British Journal of Cancer, 78, 439-445.
  • LAWS, A. L., MATTHEW, A. M., DOUBLE, J. A. and BIBBY, M. C., 1995, Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. British Journal of Cancer, 71, 1204-1209.
  • Li, L., ROJIANI, A. and SIEMANN, D. W., 1998, Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 42, 899-903.
  • MAXWELL, R. J., NIELSEN, F. U., BREIDAHL, T., STØDKILDE-JØRGENSEN, H. and HORSMAN, M. R., 1998, Effects of combretastatin on m urine tumours monitored by 31P MRS, 'H MRS and 'H MRI. International Journal of Radiation Oncology, Biology, Physics, 42, 891-894.
  • OVERGAARD, J., 1980, Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. International Journal of Radiation Oncology, Biology, Physics, 6, 1507-1517.
  • PHILPOTT, M., JOSEPH, W. R., CROSIER, K. E., BAGULEY, B. C. and CHING, L.-M., 1997, Production of tumour necrosis factor-a by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). British Journal of Cancer, 76, 1586-1591.
  • REWCASTLE, G. W., ATWELL, G. J., ZHUANG, L., BAGULEY, B. C. and DENNY, W. A., 1991, Potential antitumor agents 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. Journal of Medicinal Chemistry, 34, 217-222.
  • SAPIRSTEIN, L. A., 1958, Regional blood flow by fractional distribution of indicators. American Journal of Physiology, 193, 161-168.
  • TOZER, G. M., PRISE, V. E., WILSON, J., LOCKE, R. J., VOJNOVIC, B., STRATFORD, M. R. L., DENNIS, M. F. and CHAPLIN, D. J., 1999, Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Research, 59, 1626-1634.
  • WILSON, W. R., Li, A. E., COWAN, D. S. M. and SUM, B. G., 1998, Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Radiation Oncology, Biology, Physics, 42, 905-908.
  • Zwi, L. J., BAGULEY, B. C., GAVIN, J. B. and WILSON, W. R., 1990, Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethylxanthenone acetic acid. British Journal of Cancer, 62, 932-934.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.